Profile
Bering Capital is a venture capital firm based in San Francisco, California, founded in 2020 by Evgeny Zaytsev and Philip Sawyer. The firm focuses on investing in innovative biotech and medical technology companies. With a team of five professionals, including two partners, Bering Capital is committed to supporting the growth of cutting-edge healthcare solutions.
The firm primarily invests in life sciences, healthtech, and enterprise applications, targeting Series C and Series D rounds. Bering Capital's investments are concentrated in the United States, and the firm manages Bering Capital Fund I with an AUM of $50 million, launched in 2021. The firm is a Registered Investment Adviser (RIA) and actively seeks new investment opportunities.
Notable portfolio companies include Coherus Biosciences - biopharmaceuticals, Atea Pharmaceuticals - antiviral therapeutics, CalciMedica - drug discovery, Dragon Vascular - vascular solutions, and Life Detection Technologies - monitoring equipment.
Industry
Bering Capital Funds
| Name | Type |
|
|
|
Size | AUM | Launch date |
|---|---|---|---|---|---|---|---|
|
Bering Capital Fund I
|
Venture Capital (VC)
|
Biotechnology
Healthcare Services
MedTech
Life Sciences
|
Pre-seed
Seed
|
North America
|
$5-10 m
|
$50 M
|
April 2021
|
Contacts
Instant access on the web. Plans from $129/month — see pricing.